Aberdeen Investments announced the September 30, 2026 distributions for its U.S. Closed-End Funds, with payments made to shareholders of record as of September 22, 2026, except for some funds paying earlier. Distributions ranged from $0.12 to $0.66 per share, paid either in cash or reinvested as new shares depending on the fund. The funds aim to provide stable income distributions supplemented by capital gains and sometimes return of capital, which may affect the fund's net assets and tax treatment. Investors should note that distributions include estimated sources like net investment income and capital gains, and final tax reporting will be provided after year-end.
Distribution payments for Aberdeen Investments U.S. Closed-End Funds were announced for September 30, 2026, with shares of record as of September 22, 2026. For readers following U.S. stocks on Pluang, here is the market snapshot as of Oct 01, 2026 03:02 WIB: out of 150 priced US stocks, 63 rose and 86 fell. Notable movers include AMAT at USD 513.99 with a 5.59% increase and Pluang order activity skewed 73% Sell / 27% Buy, CVNA at USD 63.75 up 5.37% with 21% Sell / 79% Buy, and FCEL at USD 16.96 up 5.08% with 7% Sell / 93% Buy. Typical hold times on Pluang range from 28 to 66 days among these stocks.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
